ClinicalTrials.gg
RecruitingNCT07683728Updated Jul 6, 2026

A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA)

An observational study in Progressive Pulmonary Fibrosis, sponsored by Zuojun Xu. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Zuojun Xu · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.

Planned enrollment
3rd of 10
600 · median 200
Started
2025
with 4 others
Observational
10 of 40
5 open now
Primary completion
2029-07
later than 16 of 17 live
Registered
40th of 40
by date

Among the 40 studies in Pulmonary Fibrosis with a site in China, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2025, is one of 10 observational ones, reaches primary completion later than 16 of the 17 other live ones, and was the 40th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This is a nationwide multicenter prospective non-interventional registry study enrolling 600 Chinese patients diagnosed with PPF over a 3-year period (9-month enrollment, 2-year follow-up, and 3 months for data analysis and publication). Eligible participants must meet the PPF criteria defined by the 2022 ATS/ERS/JRS/ALAT guidelines, while patients with IPF, no baseline chest HRCT, or refusal to sign informed consent will be excluded. The primary endpoint is the absolute change in FVC (mL) at 1- and 2-year follow-ups. The core objective is to investigate real-world disease progression in Chinese PPF patients, with secondary objectives to analyze their clinical characteristics, current treatment status, and unmet clinical needs.

03

Conditions studied

  • Progressive Pulmonary Fibrosis

Browse trials for

Keywords

  • Progressive Pulmonary Fibrosis
  • Registry Study
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with PPF in China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of PPF within the past year, according to the 2022 ATS/ERS/JRS/ALAT guidelines;
  2. Patients who are willing to participate in the study and have signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Patients diagnosed with IPF.
  2. Patients without baseline chest HRCT.
  3. Patients who refuse to sign the form.
  4. Patients participating in other clinical trials for medications. (Patients who have completed other trials or are in an unblinded phase after a of 2 weeks are eligible for enrollment.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Chinese PPF Prospective Registry Cohort
06

What researchers measure

Primary outcomes

  1. Absolute change in FVC (mL)

    Absolute change in FVC (mL) at 1-year and 2-year follow-up.

    Time frame: at 1-year and 2-year follow-up

Secondary outcomes

  1. CTD-ILD, HP, iNSIP, exposure-related ILD, sarcoidosis, unclassified ILD, and other ILDs

    The percentage of patients with CTD-ILD, HP, iNSIP, exposure-related ILD, sarcoidosis, unclassified ILD, and other ILDs at baseline and following 2 years of follow-up.

    Time frame: at baseline and after 2 years of follow-up

  2. The percentage of patients who meet at least two of the following three inclusion criteria for PPF

    The percentage of patients who meet at least two of the following three inclusion criteria for PPF at baseline, 1-year, and 2-year follow-up: 1. Worsening respiratory symptoms; 2. Physiological evidence of disease progression (FVC decline \>5% or DLCO 3. Imaging evidence of disease progression (e.g., increased or worsened traction bronchiectasis, new ground-glass opacities with traction bronchiectasis, new reticular patterns, or new honeycombing).

    Time frame: at baseline, 1-year, and 2-year follow-up

  3. The percentage of patients receiving treatment with corticosteroids, immunosuppressive agents, and antifibrotic drugs or PDE4B inhibitors

    The percentage of patients receiving treatment with corticosteroids, immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, azathioprine, and other commonly used immunosuppressants for ILDs), and antifibrotic drugs (nintedanib, pirfenidone) or PDE4B inhibitors (e.g., nerandomilast) during the 2-year follow-up period.

    Time frame: during the 2-year follow-up period

  4. Change in absolute DLCO of pulmonary function expressed as percent predicted

    Change in absolute DLCO of pulmonary function expressed as percent predicted after 1 year and 2 years of follow-up.

    Time frame: after 1 year and 2 years of follow-up

  5. Changes in the absolute score of the dyspnea severity questionnaire

    Changes in the absolute score of the dyspnea severity questionnaire at 1-year and 2-year follow-up.

    Time frame: at 1-year and 2-year follow-up

  6. Changes in the absolute score of the Cough Severity Numerical Rating Scale (CNSRS)

    Changes in the absolute score of the Cough Severity Numerical Rating Scale (CNSRS) at 1-year and 2-year follow-up.

    Time frame: at 1-year and 2-year follow-up

  7. Frequency of acute exacerbations of ILD

    Frequency of acute exacerbations of ILD during the 2-year follow-up.

    Time frame: during the 2-year follow-up

  8. Time to first acute exacerbation

    Time to first acute exacerbation during the 2-year follow-up.

    Time frame: during the 2-year follow-up

  9. The percentage of patients with acute exacerbations, lung transplantation, or death

    The percentage of patients with acute exacerbations, lung transplantation, or death at 2-year follow-up.

    Time frame: at 2-year follow-up

  10. The percentage of patients with ILD progression (FVC decline >10% of predicted value)

    The percentage of patients with ILD progression (FVC decline \>10% of predicted value) at 2-year follow-up

    Time frame: at 2-year follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2029, 46 months after the start.

Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's planned 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 6, 2026
StartActual
Sep 23, 2025
Primary completionEst.
Jul 31, 2029
CompletionEst.
Oct 31, 2029
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07683728
Lead sponsor
Zuojun Xu
Responsible party
Zuojun Xu (Chief Physician, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Jul 6, 2026
Start date
Sep 23, 2025
Primary completion
Jul 31, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Jul 6, 2026

Study contacts

Zuojun Xu Zuojun Xu
Contact
xuzi@hotmail.com
+86 13671345136

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion